2025-05-15T17:01:39+00:00 2024-06-30 990 2023-07-01 730580274 Oklahoma Medical Research Foundation OKLA 4052717421 825 NE 13th Street Oklahoma City OK 73104 Tim Hassen VP and Chief Financial Officer 4052717421 2025-05-15 true 2023 2025-03-06 01:10:19Z Tim Hassen VP and CFO 825 NE 13th Street Oklahoma City OK 73104 214508651 false X www.omrf.org X 1946 OK Oklahoma Medical Research Foundation (OMRF) is dedicated to developing a better understanding of and more effective treatments for human disease. 64 64 643 64 0 0 71342417 88644965 30761232 29301960 5086620 7458610 7121391 6926766 114311660 132332301 0 0 46111500 51893083 0 3267148 61973997 67811404 108085497 119704487 6226163 12627814 485930868 528771950 34892698 39302223 451038170 489469727 X OMRF is dedicated to developing a better understanding of more effective treatments for human disease. false false 45331548 22893932 Arthritis and Clinical Immunology/Clinical Operations - After being redesignated in 2024 as one of only seven Autoimmunity Centers of Excellence recognized by the National Institutes of Health, OMRF continued to blaze new paths in researching and treating autoimmune diseases. The foundation received a trio of major new federal grants to study these illnesses. Meanwhile, OMRF caregivers treated more than 3,000 patients living with multiple sclerosis, lupus, rheumatoid arthritis and other diseases in which the body turns its immune system against itself. 10653127 13145938 Cardiovascular Biology Research Program - Early-career scientists led a watershed year for the study of diseases of the heart, blood and circulatory system. Together, graduate students and postdoctoral fellows in this program earned 11 research grants and fellowships, which could blaze new treatment paths for illnesses ranging from heart attack and stroke to diabetes-related vision loss. Meanwhile, the program's leader, Dr. Lijun Xia, led research that could one day lead to a new drug to treat the pain crises in sickle cell disease. Finally, an experimental therapy born from discoveries in this program began clinical trials in patients with hemophilia, the inherited blood disorder that can be life-threatening. 9467170 10981629 Aging and Metabolism Research Program - Drs. Michael Beckstead and Harris Blankenship made a groundbreaking discovery that could one day transform the lives of Alzheimer's patients. In experiments with mice genetically engineered to develop a condition that mimics Alzheimer's disease, they found that dopamine - a brain chemical associated with behavioral rewards - could play a crucial role in causing the deadly, memory-robbing disease. The scientists published their findings in 2024 in the influential scientific journal Nature Communications. "We've at least cracked the surface of something that might slow down this terrible disease," said Beckstead. "With more work, we hope we can make a big difference." 45340085 34127600 Other program services include departments such as Cell Cycle and Cancer Biology, Genes and Human Disease, Center for Biomedical Data Sciences and other scientific and research support services. 45340085 34127600 110791930 true true false true false false false false true true true false true true true true true false false true false false false true false false false false true true false false false false false false false false false false true false false false true false false false false true 219 0 true 643 true true true false false false true true true true false false false true true false false false X 64 64 false false false false false false false true true false false true true true true true true true true false OK X X Tim Hassen VP and Chief Financial Officer 4052717421 825 NE 13th Street Oklahoma City OK 73104 Ann Felton Board Member 1.0 X 0 0 0 Barbara Braught Board Member 1.0 X 0 0 0 Barry Pollard MD Board Member 1.0 X 0 0 0 Becky Switzer Board Member 1.0 X 0 0 0 Betsy Thorpe Board Member 1.0 X 0 0 0 Bill Anoatubby Board Member 1.0 X 0 0 0 Bill Hawley MD Board Member 1.0 X 0 0 0 Bond Payne Board Member 1.0 X 0 0 0 Brett Jameson MD Board Member 1.0 X 0 0 0 Brooks Hall Board Member 1.0 X 0 0 0 Bruce Benbrook Board Member 1.0 X 0 0 0 Burns Hargis Board Member 1.0 X 0 0 0 Carl Edwards Board Member 1.0 X 0 0 0 Christy Everest Board Member 1.0 X 0 0 0 Claire Eagan Board Member 1.0 X 0 0 0 Cliff Hudson Board Member 1.0 X 0 0 0 Dan Little Board Member 1.0 X 0 0 0 David Rainbolt Board Member 1.0 X 0 0 0 Dee Replogle Board Member 1.0 X 0 0 0 Ellen Burgess Board Member 1.0 X 0 0 0 Gerald Gamble Board Member 1.0 X 0 0 0 Greg Walton MD Board Member 1.0 X 0 0 0 Harrison Levy Board Member 1.0 X 0 0 0 Hiram Champlin Board Member 1.0 X 0 0 0 Jack McCarty Board Member 1.0 X 0 0 0 Jack Stark Board Member 1.0 X 0 0 0 Jacqui Haglund Board Member 1.0 X 0 0 0 Jerome Holmes Board Member 1.0 X 0 0 0 JII Boghetich Board Member 1.0 X 0 0 0 Jim Morris Board Member 1.0 X 0 0 0 John Griffin Board Member 1.0 X 0 0 0 John Saxon III MD Board Member 1.0 X 0 0 0 Judy Hatfield Board Member 1.0 X 0 0 0 Karin Holsted Board Member 1.0 X 0 0 0 Lance Benham Board Member 1.0 X 0 0 0 Larry Nichols Board Member 1.0 X 0 0 0 Leigh Ann Albers Board Member 1.0 X 0 0 0 Len Cason Board Member 1.0 X 0 0 0 Lisa Dillingham Board Member 1.0 X 0 0 0 Mark Collins PHD Board Member 1.0 X 0 0 0 Mark Funke Board Member 1.0 X 0 0 0 Martin Bautista MD Board Member 1.0 X 0 0 0 Mautra Jones EdD Board Member 1.0 X 0 0 0 Meg Salyer Board Member 1.0 X 0 0 0 Michael Cawley Board Member 1.0 X 0 0 0 Mike Carolina Board Member 1.0 X 0 0 0 Mindy Mahaney Board Member 1.0 X 0 0 0 Pat Rooney Board Member 1.0 X 0 0 0 Paul Schulte Board Member 1.0 X 0 0 0 Rainey Williams Jr Board Member 1.0 X 0 0 0 Ramsey Drake Board Member 1.0 X 0 0 0 Randy Brown MD Board Member 1.0 X 0 0 0 Randy Hogan Board Member 1.0 X 0 0 0 Rebecca Patten Board Member 1.0 X 0 0 0 Richard Parry Board Member 1.0 X 0 0 0 Ronnie Irani Board Member 1.0 X 0 0 0 Ross Swimmer Board Member 1.0 X 0 0 0 Sarah Yauk Board Member 1.0 X 0 0 0 Sharon Bell Board Member 1.0 X 0 0 0 Steven Taylor Board Member 1.0 X 0 0 0 Terence Kern Board Member 1.0 X 0 0 0 Tricia Everest Board Member 1.0 X 0 0 0 Virginia Groendyke Board Member 1.0 X 0 0 0 Walt Duncan IV Board Member 1.0 X 0 0 0 Adam Cohen SVP and General Counsel 50.0 X 339134 0 59889 Andrew Weyrich PhD President and CEO 50.0 X 782054 0 56763 Courtney Greenwood VP of Human Resources 50.0 X 216882 0 44905 Courtney Griffin PhD VP of Research 50.0 X 309221 0 62457 Judith James EVP and Chief Medical Officer 50.0 X 523931 0 107721 Lisa Day VP of Government Relations and Advocacy 50.0 X 207669 0 38677 Penny Voss VP of Philanthropy and Community Relations 50.0 X 607800 0 43105 Tim Hassen VP and Chief Financial Officer 50.0 X 304661 0 69867 Benjamin Miller PhD Program Chair, Aging and Metabolism 50.0 X 196258 0 24475 Gabriel Pardo MD Professor Clinical Neurology, Arthritis and Clinical Immunology 50.0 X 417669 0 56100 Lijun Xia MD Program Chair, Cardiovascular Biology 50.0 X 338683 0 70467 Patrick Gaffney MD Program Chair, Genes and Human Disease 50.0 X 321243 0 63125 Chelsea Berkley MD Clinical Assistant Professor, Arthritis and Clinical Immunology 50.0 X 265927 0 34893 Florea Lupu PhD Professor, Cardiovascular Biology 50.0 X 357661 0 43044 Joan Merrill MD Professor, Arthritis and Clinical Immunology 50.0 X 259621 0 28170 Matlock Jeffries MD Associate Professor, Arthritis and Clinical Immunology 50.0 X 254748 0 43587 Swapan Nath PhD Professor, Arthritis and Clinical Immunology 50.0 X 329298 0 51404 6032460 0 898649 86 false true false Infusion Management LLC 11233 Shadow Creek Pwky Suite 303 Pearland TX 77584 Infusion Management Services 23459257 Aramark 24863 Network Pl Chicago IL 606731248 HouseKeeping Services 651320 Grant Thornton LLP 211 N Robinson Suite 1200 Oklahoma City OK 73102 Audit services 126500 CapTrust Partners LLC 6305 Waterford Blvd 120 Oklahoma City OK 73118 Investment Management Services 112300 4 100892 1264561 52209498 35070014 1585317 88644965 Clinic Revenue 621990 29301960 29301960 0 0 0 0 29301960 29719710 29719710 148400 148400 4657684 3217117 1440567 432780 432780 0 432780 432780 59468154 0 81339179 538475 -21871025 -538475 -22409500 -22409500 74200 1264561 298696 -224496 -224496 Laboratory Income 621500 1608523 1608523 Cafe Income 722514 452275 452275 0 0 0 0 2060798 132332301 34127600 0 9559736 4565206 3466938 490468 607800 35378920 32925608 1476290 977022 2662894 2426126 131115 105653 6912969 6245547 400349 267073 2373094 2162093 116846 94155 158391 116408 41983 137020 137020 89156 89156 3148252 3148252 0 0 1097376 528408 75497 493471 2482514 1971772 415270 95472 5538871 4508338 1030533 915039 835365 43117 36557 420374 153768 106 266500 59865 58125 1740 8339041 8011959 327082 650089 477776 172313 Lab supplies 8491057 8483693 7364 Trainee costs 801038 801038 Inhouse 3005976 2982521 13051 10404 Subcontracts 28913514 28913514 3563831 2574682 683472 305677 119704487 110791931 5645408 3267148 3640 3640 16174000 44170006 10754989 14620131 8468635 9054128 0 0 0 0 104329 79411 7785 1174683 832803 1008212 248567792 162935837 84356351 85631955 158961816 177316130 30261701 32687772 0 176004819 163025882 485930868 528771950 12345917 18280141 2725269 2838255 10935000 7875000 0 0 8886512 10308827 34892698 39302223 X 161089274 195929685 289948896 293540042 451038170 489469727 485930868 528771950 X 12627814 20277420 5526323 X false true X true true true X 60164768 91435276 70293950 71342417 88644965 381881376 0 0 60164768 91435276 70293950 71342417 88644965 381881376 71856721 310024655 3495987 8109982 15219254 11853866 31741457 70420546 5337 10725 51456 0 0 67518 295959 158503 260020 425851 526475 1666808 454036248 157913744 0.6828 0.7334 X Schedule A, Part II, Line 10 Schedule A, Part II, Line 10 Other income includes cafeteria sales as well as fundraising income that was not included in contributions. Schedule A, Part II, Line 10 Other Income DESCRIPTION - , COLUMN A - 295959.0, COLUMN B - 158503.0, COLUMN C - 260020.0, COLUMN D - 425851.0, COLUMN E - 526475.0, COLUMN F - 1666808.0; RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED false true false false false false true 480532 false false 480532 false Schedule C, Part II-B, Line 1 DETAILED DESCRIPTION OF THE LOBBYING ACTIVITY The Foundation's lobbying activities entail monitoring proposed legislation and educating legislators and their staffs about the Foundation, medical research and the impact of proposed legislation on medical research and the Foundation. 177673255 1162889 25868268 7400000 197304412 158042345 7689037 17641873 5700000 177673255 169632776 12453227 -18843658 5200000 158042345 116281093 18987421 39164262 0 4800000 0 169632776 115938978 26722 4715393 0 4400000 0 116281093 0.3434 0.3318 0.3248 true false 4080847 4080847 189089808 128073169 61016639 53082759 34601058 18481701 2314378 261610 2052768 85631955 Other securites 32687772 F 32687772 Funds held in trust by others 151192976 Wills and Bequests 2341633 Cash Surrender Value of Life Insurance 8148130 Debt Issue Costs 53235 Deposits 1013169 Accrued Interest Receivable 211100 Assets Held for Sale 65520 Minerals 119 163025882 Postretirement Benefits and Deferred Comp 9198657 Split Interest Agreements 260955 Long-term Lease Liability 849215 10308827 X 158136044 20277420 5526323 25803743 132332301 0 0 132332301 119704487 0 0 119704487 0 0 119704487 Schedule D, Part XI, Line 2(d) Includes change in fair value of funds held in trust by others of $5,169,183 as well as pension related changes other than net periodic pension costs of $357,140. Schedule D, Part V, Line 4 Intended uses of endowment funds The Foundation's endowment consists of individual funds established to provide the Foundation with funding in perpetuity. Schedule D, Part X, Line 2 FIN 48 (ASC 740) footnote The Foundation is a public foundation exempt from federal income tax under section 501(c)(3) of the internal revenue code except for amounts relating to unrelated business income. There were no known material unrelated business income taxes incurred in 2024 and accordingly, no provision for income taxes has been made in these financial statements. Management has reviewed the Foundation's tax position and concluded that there are no uncertain tax positions that require accrual in the consolidated financial statements or disclosure in the footnotes to be in compliance with authoritative literature. Generally, the Foundation is no longer subject to income tax examination by federal, state or local tax authorities for years prior to 2021. The statute of limitations will remain open for both federal and state purposes for any returns not filed. Schedule D, Part XI, Line 2(d) Other revenues in audited financial statements not in form 990 Changes in Fair Value of Funds Held in Trust - 5169183 Pension Related Changes Other Than Net Periodic Pension Costs - 357140 Europe (Including Iceland and Greenland) 0 36 Conference Travel 126220 Europe (Including Iceland and Greenland) 0 8 Program Services Student Program 20744 North America (Canada & Mexico only) 0 11 Conference Travel 33331 South Asia 0 1 Conference Travel 3966 South America 0 3 Conference Travel 7472 East Asia and the Pacific 0 1 Conference Travel 140 North America (Canada & Mexico only) 0 0 Investments 2195647 Central America and the Caribbean 0 0 Investments 14998148 0 60 0 0 0 60 17385668 0 17385668 true false false true true false Schedule F, Part I, Line 3 Method used to account for expenditures on org's financial statements CENTRAL AMERICA AND THE CARIBBEAN-Accrual; EAST ASIA AND THE PACIFIC-Accrual; EUROPE (INCLUDING ICELAND AND GREENLAND)-Accrual; NORTH AMERICA (CANADA & MEXICO ONLY)-Accrual; SOUTH AMERICA-Accrual; SOUTH ASIA-Accrual 241 EVENT 949961 889861 60100 60000 28662 63350 106563 MS DINNER 388800 374700 14100 1500 19890 3446 15285 0 1338761 1264561 74200 61500 48552 66796 121848 298696 -224496 X X X true true X X X X X false true false false false false false true false Andrew Weyrich PhD President and CEO 626322 0 100000 0 55732 0 36079 0 20684 0 838817 0 0 0 Adam Cohen SVP and General Counsel 313732 0 150 0 25252 0 47732 0 12157 0 399023 0 0 0 Penny Voss VP of Philanthropy and Community Relations 256243 0 125 0 351432 0 29040 0 14065 0 650905 0 329648 0 Tim Hassen VP and Chief Financial Officer 283834 0 75 0 20752 0 47833 0 22034 0 374528 0 0 0 Lisa Day VP of Government Relations and Advocacy 203728 0 0 0 3941 0 26795 0 11882 0 246346 0 0 0 Courtney Greenwood VP of Human Resources 212142 0 0 0 4740 0 26442 0 18463 0 261787 0 0 0 Judith James EVP and Chief Medical Officer 473843 0 0 0 50088 0 95199 0 12522 0 631652 0 0 0 Courtney Griffin PhD VP of Research 297461 0 0 0 11760 0 41133 0 21324 0 371678 0 0 0 Gabriel Pardo MD Professor Clinical Neurology, Arthritis and Clinical Immunology 413885 0 0 0 3784 0 35416 0 20684 0 473769 0 0 0 Patrick Gaffney MD Program Chair, Genes and Human Disease 305334 0 125 0 15784 0 42441 0 20684 0 384368 0 0 0 Benjamin Miller PhD Program Chair, Aging and Metabolism 184146 0 10000 0 2112 0 16166 0 8309 0 220733 0 0 0 Lijun Xia MD Program Chair, Cardiovascular Biology 287241 0 150 0 51292 0 60728 0 9739 0 409150 0 0 0 Swapan Nath PhD Professor, Arthritis and Clinical Immunology 287862 0 0 0 41436 0 33332 0 18072 0 380702 0 0 0 Florea Lupu PhD Professor, Cardiovascular Biology 334771 0 0 0 22890 0 34993 0 8051 0 400705 0 0 0 Matlock Jeffries MD Associate Professor, Arthritis and Clinical Immunology 230612 0 0 0 24136 0 32431 0 11156 0 298335 0 0 0 Joan Merrill MD Professor, Arthritis and Clinical Immunology 236649 0 0 0 22972 0 26685 0 1485 0 287791 0 0 0 Chelsea Berkley MD Clinical Assistant Professor, Arthritis and Clinical Immunology 265020 0 75 0 832 0 27856 0 7037 0 300820 0 0 0 Schedule J, Part I, Line 1a First-class or charter travel First class travel is allowed for the CEO to allow him to accomplish work related to tasks while traveling. Schedule J, Part I, Line 1a Travel for companions Travel for companions is allowed in certain limited circumstances where the companion's presence has a benefit to the Foundation but does not qualify as a business expense under IRS rules. In those limited cases the companion's travel expenses are treated as taxable compensation. Schedule J, Part I, Line 1a Tax indemnification and gross-up payments The Foundation's policy is to provide gross-up payments for all employee relocation expenses. Schedule J, Part I, Line 4b Supplemental nonqualified retirement plan The Board of the Foundation periodically uses non-qualified retirement plans as a retention tool. The amount reported is the amount vested in the 457(f) plan. The remaining amount of the plan is not vested and is subject to substantial risk of forfeiture. Schedule J, Part I, Line 7 Non-fixed payments The President receives an annual bonus that is determined by leadership of the board of directors based on performance. The bonus is considered as a portion of total compensation and is subject to the review process previously described. Schedule J, Part I, Line 3 Compensation for the CEO is determined by leadership of the board of directors based on comparability data from widely accepted peer benchmarking surveys that are segmented by region and size of entity. A Oklahoma Industries Authority Revenue Bonds (OMRF Project) Series 2016 736194355 000000000 2016-07-13 29535000 Refunding of prior year 2008 bond false false false A 18600000 0 29535000 2953564 0 26315325 266175 0 0 0 0 0 2016 false true true true A false false false true true 0.0 0.0 0.0 false false true A false false false true false false false false true A true Schedule K, Part I 07/13/2016 29535000 Oklahoma Industries Authority In July 2016, the Foundation entered into advanced refinancing of the Series 2008 bonds. The Foundation issued $43,955,000 of OIA Series 2008 Revenue Bonds (the "Series 2008 Bonds") dated July 1, 2008; the proceeds from this bond were used to construct and equip a new research facility. The Series 2008 Bonds were defeased when the Foundation issued $29,535,000 of OIA Series 2016 Revenue Bonds (the "Series 2016 Bonds") dated July 13, 2016. The Series 2016 Bonds mature on July 1, 2026 and bear interest at the stated rate of 1.81% per annum. Payments of principal and interest began January 1, 2017 and are due January 1st and July 1st of each year. The Series 2016 Bond agreements also require maintenance of a reserve fund which is included in investments in the accompanying statement of financial position. This amount was $2,953,500 as of June 30, 2024. Schedule K, Part IV, Line 2c COLUMN A Issuer name: Oklahoma Industries Authority Revenue Bonds (OMRF Project) Series 2016 The calculation for computing no rebate due was performed on 07/01/2021 X 17 1585317 Market value 0 false true true Schedule M, Part I, Line 32b Third parties used to solicit, process, or sell noncash contributions The Foundation contracts with a service organization who solicits the donation of vehicles. The service organization is responsible for communication with the donor as well as the selling process. The Foundation receives a check for 80% of the proceeds from the sale of the vehicle. Form 990, Part III, Line 4d Description of other program services (Expenses $ 45,340,085 including grants of $)(Revenue $ 34,127,600) Other program services include departments such as Cell Cycle and Cancer Biology, Genes and Human Disease, Center for Biomedical Data Sciences and other scientific and research support services. Form 990, Part VI, Line 1a Delegate broad authority to a committee The Foundation's Board of Directors has delegated all of its powers to the Foundation's Executive Committee, except as follows: establish the overall policies and direction of the Foundation, appoint the members of the Executive Committee, elect and remove the Chair of the Board of Directors, amend the Bylaws and the Certificate of Incorporation of the Foundation, and appoint special committees to the Board of Directors. The Board of Directors may at any time amend or revoke this delegation of powers. Form 990, Part VI, Line 11b Review of form 990 by governing body The Form 990 is prepared by the Foundation, internally reviewed by the CFO. The Form 990-T is externally reviewed by the tax department of a public accounting firm. A summary of the Form 990 is presented for review to the Executive Committee. Subsequent to that review, the Form 990 with all supplemental schedules is made available to all members of the board of directors for review and comment prior to filing. Form 990, Part VI, Line 12c Conflict of interest policy Each director, officer and key employee is annually provided with a copy of the Foundation's conflict of interest policy. Each of these individuals is annually provided with a questionnaire regarding potential conflicts and required to disclose any potential conflict that he or she might have. In addition, each of these individuals must annually sign a statement affirming that he or she has; received a copy of the conflicts of interest policy, read and understood the policy and agrees to comply with the policy. Once the Foundation has collected annual disclosure statements from all directors, officer and key employees, the Foundation's Governance Committee reviews such information to identify situations in which a potential conflict exists and is material. If a potential material conflict is identified, the committee analyzes whether the contemplated transaction may be authorized as just, fair, and reasonable to the Foundation. The Governance Committee then makes a recommendation to the Foundations' Executive Committee regarding the management of all potential conflicts it has identified. The final decision as to the approval and , where applicable, management of all such potential conflicts rests in the sole discretion of the Executive Committee, which makes such decisions based upon the welfare of the Foundation and the advancement of its purpose. The recommendations of the Governance Committee and decisions of the Executive Committee are documented in the respective minutes of these Committees' regular meetings. Form 990, Part VI, Line 15a Process to establish compensation of top management official Compensation for officers and key employees is determined and evaluated in May of each year by the executive committee of the board of directors based on comparability data from widely accepted peer bench marking salary surveys that are segmented by region and size of entity. Form 990, Part VI, Line 15b Process to establish compensation of other employees Compensation for officers and key employees is determined and evaluated in May of each year by the executive committee of the board of directors based on comparability data from widely accepted peer bench marking salary surveys that are segmented by region and size of entity. Form 990, Part VI, Line 18 How forms are made available to the public The Foundation's Form 990 for the last three years are publicly available on the Foundation's website, as well as on Guidestar and other nonprofit databases. Form 1023, 990, and 990-T are provided upon request. Form 990, Part VI, Line 19 Required documents available to the public The Foundation's governing documents, conflict of interest policy, and financial statements are provided upon request and are publicly available on the Foundation's website. Form 990, Part XI, Line 9 Other changes in net assets or fund balances CHANGES IN FAIR VALUE OF FUNDS HELD IN TRUST - 5169183; PENSION RELATED CHANGES OTHER THAN NET PERIODIC PENSION COSTS - 357140; Schedule F, Part I, Line 3 Program service activity in all regions includes scientists attending and/or speaking at scientific conferences and collaborations. OMRF does not maintain ongoing operations in foreign jurisdictions however the Foundation's scientists do travel to various scientific conferences in other countries to share in scientific discoveries, as well as, to learn from other scientists across the world. Form 990, Part VI Section A, Line 2 The Foundation currently has 64 directors, many of whom are business leaders and members of prominent families in the State of Oklahoma. The Foundation believes there are multiple business relationships between and among board members and families of Board members, but the Foundation review of signed conflict of interest disclosures from all board members and of the Foundation's ledger accounts indicated there are no such relationships that would impair the fiduciary duties of any director to the Foundation. Culbertson Plaza LLC 825 NE 13th Street Oklahoma City OK 73104 842527142 Manage real property known as the Culbertson Plaza Shopping Center OK 148958 1342203 Oklahoma Medical Research Foundation